Hemosiderosis is a condition in which excess iron accumulates in your body’s tissues, stored in a form called hemosiderin. Unlike hemochromatosis, which involves iron buildup that actively damages organs, hemosiderosis technically refers to iron deposition that hasn’t yet caused significant organ dysfunction. In practice, though, the line between the two blurs: unchecked iron accumulation can progress to tissue damage over time, making early detection important.
How Iron Builds Up in Tissues
Your body has no efficient way to excrete large amounts of iron. Normally, cells store iron in a protein called ferritin, which keeps it safely contained. When iron levels exceed what ferritin can handle, the excess gets converted into hemosiderin, a more stable but harder-to-mobilize storage form that collects inside immune cells called macrophages. In the liver specifically, hemosiderin is the predominant form of stainable iron, accumulating in both liver cells and the specialized macrophages that line the organ’s blood-filtering channels.
This buildup can be localized or systemic. Localized hemosiderosis happens in areas where bleeding has occurred. After a hemorrhage, macrophages at the site convert hemoglobin’s iron into hemosiderin within about 72 hours, and those iron-loaded cells can linger for 4 to 8 weeks. Systemic hemosiderosis spreads iron across multiple organs, with the liver, heart, and pancreas bearing the heaviest deposits.
Common Causes
The most frequent cause of systemic hemosiderosis is repeated blood transfusions. Each unit of donated red blood cells delivers a significant dose of iron, and patients who receive many units over time have no way to clear it. A study at a Dutch university medical center found that among 471 patients who received more than 20 units of red blood cells, nearly 47% of those transfused over a long period developed hemosiderosis. Even among patients who received all their transfusions in a short burst, 12% still showed iron overload.
People with blood disorders requiring regular transfusions are at highest risk. This includes conditions like thalassemia, sickle cell disease, and myelodysplastic syndromes. Other causes include excessive dietary iron absorption (as seen in certain inherited conditions), chronic liver disease, and repeated hemorrhages within specific organs.
Hemosiderosis vs. Hemochromatosis
These two terms are often confused, and even medical literature sometimes uses them loosely. The key distinction: hemosiderosis describes iron accumulation itself, while hemochromatosis refers to iron overload that has progressed to organ damage. Hemochromatosis can be hereditary (caused by a genetic mutation that makes the gut absorb too much iron) or secondary (caused by transfusions or other external sources).
In hereditary hemochromatosis, iron accumulates primarily inside organ cells like hepatocytes and bile duct lining. In transfusion-related overload, iron tends to collect first in macrophages, the immune cells that process old red blood cells. This difference in where iron sits within the tissue matters for how quickly damage develops, but both patterns can eventually lead to the same complications: liver scarring, heart failure, diabetes, and a characteristic bronze or gray skin discoloration sometimes called “bronze diabetes.”
Pulmonary Hemosiderosis
Pulmonary hemosiderosis is a distinct, localized form of the condition that affects the lungs. It develops when repeated episodes of bleeding into the lung’s air sacs leave behind iron-laden macrophages. The idiopathic form, meaning no identifiable cause, is rare and occurs most often in children. It’s characterized by a classic triad: coughing up blood, iron deficiency anemia, and widespread shadowing on a chest X-ray.
The condition is tricky to diagnose because its symptoms, including chronic cough, fatigue, and shortness of breath, overlap with many common respiratory illnesses. The anemia happens because iron keeps getting trapped in the lungs rather than recycling back into the bloodstream, so blood tests show low serum iron despite the body technically having plenty of it stored in the wrong place. Diagnosis typically involves finding hemosiderin-loaded macrophages in sputum or lung fluid samples.
Historically, children diagnosed with idiopathic pulmonary hemosiderosis survived an average of just 2.5 years. Outcomes have improved dramatically with modern treatment: about 86% of patients now survive beyond 5 years. A long-term follow-up study of 15 children treated with sustained steroid therapy found that 80% went on to lead normal lives over an average follow-up period of more than 17 years.
Symptoms to Recognize
Systemic hemosiderosis often produces no symptoms in its early stages, which is part of what makes it dangerous. The first signs tend to be vague: fatigue, weakness, and general malaise. As iron continues to accumulate over months or years, symptoms become more specific depending on which organs are affected.
- Liver: Iron deposits can lead to an enlarged liver, abnormal liver function, and eventually cirrhosis if the overload progresses to true hemochromatosis.
- Heart: Iron in heart tissue can cause irregular rhythms and, in severe cases, heart failure.
- Pancreas: Damage to insulin-producing cells can trigger diabetes.
- Skin: A bronze or grayish discoloration develops as iron deposits accumulate.
- Eyes: Vision changes can occur in advanced cases.
These complications develop over years, not weeks. The slow progression is why screening matters for people who receive frequent transfusions, yet a study found that only about 39% of heavily transfused patients were adequately screened for iron overload.
How It’s Diagnosed
The primary screening tool is a blood test measuring serum ferritin, a protein that reflects total body iron stores. Normal ferritin levels vary by age and sex, but in the context of transfusion-related overload, ferritin at or above 1,000 micrograms per liter is generally considered the threshold for hemosiderosis. Research in patients with thalassemia has identified more specific cutoffs: ferritin above roughly 1,090 ng/mL showed the best balance of accuracy for detecting liver iron overload, while levels above approximately 2,027 ng/mL were associated with cardiac iron deposits.
These blood tests aren’t perfect. Ferritin can be elevated by inflammation, infection, and liver disease independent of iron status. For a more precise picture, MRI scans can directly measure iron concentration in the liver and heart. This imaging approach has become the gold standard for monitoring iron levels in patients who need ongoing transfusions. Tissue biopsy, where a pathologist stains a small sample to visualize hemosiderin deposits directly, remains the most definitive method but is more invasive.
Treatment and Management
The cornerstone of treating systemic hemosiderosis is iron chelation therapy, which uses medications that bind to excess iron so your body can excrete it. Three chelating agents are widely used, each with a different route and schedule. One is given as a slow infusion under the skin or into a vein, typically overnight for 8 to 12 hours at least six nights per week. A second option is taken by mouth three times daily. A third is an oral tablet taken once daily, which has become increasingly popular for its convenience.
The choice depends on the severity of iron overload, the patient’s age, tolerance for side effects, and lifestyle considerations. Nightly infusions are effective but demanding to maintain. Oral options improve adherence but require regular monitoring of kidney and liver function. For many patients with chronic transfusion needs, chelation therapy becomes a lifelong commitment that runs alongside their transfusion schedule.
For pulmonary hemosiderosis, treatment focuses on suppressing the immune-mediated bleeding with steroids, sometimes combined with other immune-suppressing medications. When hemosiderosis results from an identifiable cause like a bleeding lesion or an underlying autoimmune condition, treating that root cause can stop further iron accumulation. The body will slowly reprocess existing hemosiderin deposits on its own once the source of excess iron is removed, though this can take months.